EUVIMEDEUVIMED entdecken
Crossref

Trilobatin ameliorates ulcerative colitis by reducing inflammation and enhancing intestinal barrier function via regulating HMGB1-mediated TLR4/NF-κB signaling pathway

Tao Chen, Wei Wang

Pathology - Research and Practice · 2026

DOI: 10.1016/j.prp.2026.156362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Tao Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu 21300, China. Hauptthemen laut MEDLINE: HMGB1 Protein, Toll-Like Receptor 4, Signal Transduction, NF-kappa B. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) stands as the predominant chronic inflammatory immune bowel disease. This research aimed to elucidate the mechanism of Trilobatin (TLB) in dextran sodium sulfate (DSS)-induced UC, utilizing DSS-induced mice and NCM460 cells as UC models. The findings of the study confirmed that TLB could ameliorate intestinal structural damage in DSS-treated mice. TLB treatment intensified ZO-1, Occludin, and Claudin-1 levels, as well as Bcl-2, and lessened the levels of Bax in DSS-treated mice. Moreover, TLB administration enhanced the activity of SOD and reduced the content of MDA, alongside decreased levels of IL-6, TNF-α, and IL-1β. In NCM460 cells, TLB promoted cell viability and suppressed apoptosis, oxidative stress, and inflammation triggered by DSS. Moreover, levels of tight junction proteins were elevated in DSS-triggered NCM460 cells following treatment with TLB. Further, TLB was found to suppress TLR4/NF-κB signaling in DSS-elicited NCM460 cells via regulating HMGB1. In conclusion, TLB exerted its protective function in DSS-induced colitis by inactivating HMGB1-mediated TLR4/NF-κB signaling, which might provide novel strategies for therapeutic intervention in UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinToll-Like Receptor 4Signal TransductionNF-kappa BColitis, UlcerativeFlavonoidsAnti-Inflammatory AgentsAnimalsIntestinal Barrier FunctionMiceInflammationHumansMaleOxidative StressDextran SulfateDisease Models, AnimalMice, Inbred C57BLPolyphenols

Stichwörter der Autor:innen

HMGB1TLR4/NF-κBTrilobatinUlcerative colitis

Substanzen

HMGB1 ProteinToll-Like Receptor 4NF-kappa BtrilobatinTlr4 protein, mouseFlavonoidsHMGB1 protein, mouseDextran SulfateAnti-Inflammatory AgentsPolyphenols

Autor:innen und Institutionen

  • Department of Gastroenterology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu 21300, China.
  • Department of Gastroenterology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu 21300, China. Electronic address: 13585336190@163.com.

Zitieren

APA

Chen, T., & Wang, W. (2026). Trilobatin ameliorates ulcerative colitis by reducing inflammation and enhancing intestinal barrier function via regulating HMGB1-mediated TLR4/NF-κB signaling pathway. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156362

Vancouver

Chen T, Wang W. Trilobatin ameliorates ulcerative colitis by reducing inflammation and enhancing intestinal barrier function via regulating HMGB1-mediated TLR4/NF-κB signaling pathway. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2026.156362

BibTeX
@article{Chen2026,
  author = {Chen, Tao and Wang, Wei},
  title = {Trilobatin ameliorates ulcerative colitis by reducing inflammation and enhancing intestinal barrier function via regulating HMGB1-mediated TLR4/NF-κB signaling pathway},
  journal = {Pathology - Research and Practice},
  year = {2026},
  doi = {10.1016/j.prp.2026.156362}
}
Kostenlos starten →